The Peptide Core Facility is designed to produce, purify and analyze synthetic peptides and anti-peptide antibodies needed for studies in the Programmatic Areas of the CFAR. Proposed activities include synthesis of peptides for the following: 1) development and testing of preventative and therapeutic HIV-1 vaccines in preclinical and clinical trials. (Preventative Vaccines: Haynes, Palker, Matthews, Bolognesi), 2) identification of targets for major histocompatibility complex (MHC) Class I cytototoxic T-lymphocytes to HIV-1 Epstein Barr Virus induced lymphomas in AIDS patients (Weinhold, Haynes, Palker, Matthews, Bolognesi), 2) identification of targets for major histocompatibility complex (MHC) Class I cytotoxic T-lymphocytes to HIV-1 and Epstein Barr Virus induced lymphomas in AIDS patients (Weinhold, Haynes, Lyerly), 3) preclinical and clinical synthetic peptides directed to testing of novel viral targets involved in HIV-1 mediated syncytium formation and HIV-1 replication (Matthews, Garcia-Blanco). Two peptide synthesis and purification facilities in the laboratories of Dr. Barton F. Haynes (Room 219, CARL Building) and Dr. Thomas J. Matthews (Room 126, SORF Building) will be included in this Core Facility; both are equipped with Applied Biosystems 431A Peptide Synthesizers, Waters of LKB Pharmacia HPLCs for analytical and preparative purification of peptides and ancillary equipment (lyophilizer, water baths) for preparation of peptides. An additional service of the facility will be to produce antipeptide antisera as probes for HIV-1 vaccine related work in the laboratories of Dr. Thomas J. Palker (Room 124, CARL Building) and Dr. Haynes. A charge back system will be phased in by the end of year 1 such that users will be reimburse the Peptide Core Facility commensurate wit usage of equipment, time supplies, and personnel. Some of the above mentioned activities are ongoing but must be centralized and expanded to accomplish the mission of the Duke CFAR. Since the initial funding of the CFAR in September, 1989, the Peptide Core Facility has provided CFAR investigators and September, 1989, the Peptide Core Facility has provided CFAR investigators and associates with nearly 400 purified, high-quality synthetic peptides and 300 anti-peptide antisera for development of novel therapeutic anti-retroviral interventional strategies and basic research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI028662-10S1
Application #
6217090
Study Section
Project Start
1999-07-01
Project End
2002-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Betts, Michael R; Exley, Barbara; Price, David A et al. (2005) Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 102:4512-7
Ferrari, Guido; Neal, Wesley; Ottinger, Janet et al. (2004) Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. J Immunol 173:2126-33
Freel, Stephanie A; Fiscus, Susan A; Pilcher, Christopher D et al. (2003) Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS 17:2025-33
Szczech, L A; Edwards, L J; Sanders, L L et al. (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57:336-41
Bartlett, John A; Miralles, G Diego; Sevin, Anne D et al. (2002) Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. AIDS Res Hum Retroviruses 18:535-43
Szczech, Lynda Anne; Gange, Stephen J; van der Horst, Charles et al. (2002) Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61:195-202
Wellons, M F; Ottinger, J S; Weinhold, K J et al. (2001) Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. J Infect Dis 183:1522-5
Demarest, J F; Jack, N; Cleghorn, F R et al. (2001) Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 17:1333-44
Pilcher, C D; Shugars, D C; Fiscus, S A et al. (2001) HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 15:837-45
Johnston, A M; Valentine, M E; Ottinger, J et al. (2001) Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study. Pediatr Infect Dis J 20:941-6

Showing the most recent 10 out of 68 publications